Jupiter Neurosciences

Jupiter Neurosciences, a clinical-stage biotech company, sees its stock drop over 25% following Nasdaq’s notification of a potential delisting from its Capital Market. The move stems from a staff determination regarding compliance with listing requirements. The company now faces uncertainty over continued public trading and investor access.

Aug 2026RTTNewsNews article

Jupiter Neurosciences, a clinical-stage biopharmaceutical company, approves a 1-for-75 reverse stock split for its common stock. The adjusted shares are set to begin trading on **August 7, 2026**, targeting neurological and neurodegenerative disorder treatments. The move follows board approval to restructure its equity.

Aug 2026Yahoo FinanceNews article

Jupiter Neurosciences raises **$2.0 million** through a registered direct offering of **7.1 million shares** of common stock. The clinical-stage biopharmaceutical company specializes in treating central nervous system disorders and neuroinflammation. D. Boral Capital LLC serves as the financial advisor for the transaction.

May 2026Yahoo FinanceNews article

Jupiter Neurosciences signs a $100 million term sheet for exclusive U.S. rights to ALA-002, an FDA-recognized MDMA therapy. The deal includes a $3.33 million upfront payment in cash and stock, following a recent U.S. government order on psychedelics. The agreement positions Jupiter as a key player in advancing MDMA-based treatments.

May 2026Stock TitanNews article